Dr. Paul Mastoridis is a globally recognized medical affairs executive, digital health innovator, and former CEO known for transforming complex challenges into scalable, patient-centered solutions. With more than 25 years of experience across pharmaceuticals, medical devices, digital therapeutics, and global healthcare systems, he has built a reputation as a visionary who delivers meaningful clinical, operational, and commercial results. His work bridges the worlds of science, medicine, technology, and strategy—positioning organizations for accelerated growth while elevating patient outcomes on a global scale.
Throughout his distinguished career, Dr. Mastoridis has been entrusted with shaping therapeutic strategies, leading multidisciplinary teams, and steering companies through pivotal milestones, including FDA approvals, global product launches, organizational redesign, and digital transformation initiatives. His leadership is defined by his ability to reimagine traditional medical affairs functions, introduce advanced AI and machine learning solutions, and cultivate cross-functional alignment that propels innovation forward. He is widely recognized for creating the first AI-powered diagnostic tool capable of differentiating asthma from COPD with superior accuracy, a breakthrough that has earned global acclaim and advanced respiratory care standards.
As Chief Executive Officer of Adherium, a publicly traded respiratory digital health company, Dr. Mastoridis led a strategic turnaround that repositioned the organization for profitability and long-term stability. He orchestrated an $8 million capital raise, secured FDA clearance for two digital adherence devices, and shifted the company from a trial-centric model to a scalable remote patient monitoring platform in partnership with two of the nation’s largest asthma networks. Under his leadership, Adherium established a transformative clinical-to-commercial bridge that connected technology, clinicians, and patients through intelligent digital pathways, supporting over 400,000 respiratory patients.
Prior to his tenure as CEO, Dr. Mastoridis spent a decade with Novartis, where he served as a global medical affairs leader across cystic fibrosis, asthma, COPD, respiratory devices, and digital health. His work helped shape the future of respiratory care, from building the first global respiratory digital ecosystem to pioneering new adherence platforms and real-world evidence strategies. He partnered with leading institutions such as the University of Toronto to test advanced patient-management technologies and spearheaded the industry’s largest adherence outcomes study (MAGNIFY) involving 1,700 patients. His contributions have reshaped how medical affairs integrates with technology, patient engagement, and global commercialization.
Dr. Mastoridis’s earlier leadership roles at Mylan and Angiotech further demonstrate his ability to build high-performing teams and design medical affairs divisions from the ground up. At both organizations, he developed the full spectrum of medical and clinical operations—including IIT programs, post-marketing research, KOL engagement, SOP infrastructure, publication strategy, regulatory partnership models, and data dissemination pathways. He consistently introduced new standards of excellence that elevated organizational credibility, accelerated product adoption, and strengthened relationships with physicians, advocacy groups, payers, and regulators.
At Mylan Specialty, Paul Mastoridis served as Vice President of Medical Affairs, where he rapidly expanded the organization into a fully integrated, strategically aligned medical engine supporting four major therapeutic areas: allergy/anaphylaxis, COPD, CNS, and anesthesiology. He built and led a 21‑person department, establishing Medical Affairs strategy, MSL infrastructure, IIT governance, publication planning, post‑marketing research, CME and grants processes, and medical device expertise.
Paul oversaw a $26M budget and delivered measurable impact across the EpiPen, Perforomist, EMSAM, and Ultiva franchises. He initiated multiple IITs and phase 4 studies, partnered with clinical development on a respiratory combination product launch, and strengthened global alliances—most notably with Pfizer and Meda—to support the worldwide EpiPen business. He also developed a healthcare professional website, modernized SOPs for operational efficiency, and led competitive strategy for medical devices in the anaphylaxis space.
His tenure is marked by organizational expansion, scientific rigor, and cross‑functional leadership that elevated Mylan’s medical credibility and strengthened its position across key therapeutic markets.
At Angiotech, Paul Mastoridis served as Vice President of Medical Affairs and Clinical Research, where he built Medical Affairs from the ground up and transformed them into fully integrated, high‑performing global organizations. He oversaw Medical Information, Compliance and Safety Surveillance, Publications, CME/Grants, MSL strategy, Clinical Operations, Health Outcomes, Pricing & Reimbursement, and digital platforms—creating a unified medical engine supporting a diverse portfolio across surgery, interventional radiology, vascular medicine, wound closure, infectious disease, aesthetics, and orthopedics.
Paul led the Global Clinical Research Department, establishing 17 worldwide SOPs and managing all phases of clinical trials, including PMA and 510(k) submissions. His leadership secured FDA PMA approval for a combination drug‑device (5‑FU/CVC) and obtained 510(k) clearance for the Hemostream hemodialysis catheter. He initiated and executed major clinical programs such as the Paclitaxel Vascular WRAP study and the Quill SRS post‑market program, while modernizing global processes in protocol development, EDC, monitoring, regulatory operations, and safety.
At Angiotech, Paul Mastoridis pioneered the company’s first physician‑facing e‑commerce platform, creating a direct‑to‑clinician channel for suture sales that bypassed traditional distribution barriers. He conceived, built, and launched the system end‑to‑end, integrating medical, commercial, and operational workflows into a seamless digital purchasing experience. The platform became an immediate commercial success—recouping its full development cost within the first month of operation—and established a new revenue model that strengthened Angiotech’s competitive position in surgical and procedural markets.
He became a trusted strategic advisor to the CEO, CMO, COO, and CFO, shaping corporate SOPs, driving cross‑functional alignment, and elevating scientific credibility through KOL engagement, publication strategy, and medical education platforms—including the creation of AngioEduPro.com. His tenure is marked by operational rigor, organizational design excellence, and the establishment of one of the strongest Medical Affairs and Clinical Research infrastructures in the mid‑market device sector.
His career began at Schering-Plough, where he launched and scaled one of the earliest large-scale Medical Science Liaison divisions in the United States. His leadership in building this nationally recognized team set new benchmarks for MSL excellence and paved the way for modern medical affairs operations. He also modernized global clinical research operations by designing the company’s first Global electronic SOP system, founding the Global SOP Committee, and launching GEOS, the most widely used clinical research intranet at Schering-Plough Research Institute (SPRI). His leadership earned multiple company awards for excellence, cross‑functional collaboration, and strategic impact, including the prestigious Schering‑Plough Excellence Award and the Strategic Purchasing Recognition Award for initiatives that saved the company more than $13 million in a single year—an early indicator of his future impact as a transformational executive.
Dr. Mastoridis is not only an experienced operator and strategist; he is an innovator who consistently bridges clinical science with emerging technologies. His patented diagnostic innovations, data-driven digital platforms, and AR-enhanced educational tools have influenced patient management across more than 18 countries. His leadership has repeatedly been recognized through global awards for innovation, external collaboration, digital excellence, and scientific advancement. He has served as a trusted advisor and board member for organizations seeking to modernize their digital and clinical infrastructures, including PKG Health, where he contributed to the advancement of digital biomarkers for neurological disorders.
Beyond his technical expertise, Dr. Mastoridis is known for his collaborative approach, patient-first philosophy, and ability to unite cross-functional stakeholders around shared long-term goals. His work consistently centers on improving patient lives while driving sustainable business growth. He has supported global teams across more than 80 countries, bringing cultural fluency, interdisciplinary expertise, and strategic foresight to every initiative he leads. Whether building teams, forging alliances, coaching future leaders, or designing next-generation medical solutions, he approaches every challenge with purpose, empathy, and unwavering commitment to scientific integrity.
His educational foundation—a Doctor of Pharmacy degree, a Clinical Research Fellowship in Renal Transplantation and Immunosuppressive Agents from the University of Minnesota, and dual bachelor’s degrees in Pharmacy and Medical Microbiology—provides a deep scientific and clinical grounding that informs his strategic leadership. This academic rigor, combined with decades of industry experience, equips him to evaluate emerging therapies, guide regulatory strategy, and shape medical and commercial roadmaps with precision.
Today, Dr. Mastoridis continues to serve organizations seeking board-level leadership that blends global medical affairs expertise with AI innovation, digital health strategy, commercial insight, and patient-centered thinking. As he transitions into expanded governance roles, he is committed to helping companies navigate an evolving healthcare landscape, unlock new market opportunities, and build scalable systems that drive long-term value. His mission remains clear: to transform healthcare through innovation, scientific excellence, and meaningful patient impact.
Character:
Dr. Mastoridis demonstrates unwavering integrity, consistently grounding his decisions in what best serves patients, scientific rigor, and organizational mission. He brings humility and curiosity to every environment, fostering trust among clinicians, executives, and global partners. His leadership style reflects compassion, accountability, and respect, ensuring teams feel valued and empowered to excel.
Knowledge:
His deep expertise spans medical affairs, digital health, AI-driven diagnostics, global clinical development, and regulatory strategy, enabling him to contribute insightfully across diverse healthcare arenas. He possesses comprehensive understanding of product lifecycle management from early development through commercialization. His scientific training and real-world experience allow him to translate complex data into actionable strategy for stakeholders at all levels.
Strategic:
Dr. Mastoridis excels at identifying long-term opportunities and designing frameworks that strengthen organizational capability, accelerate growth, and optimize patient outcomes. He anticipates market shifts and healthcare trends, allowing companies to remain agile and competitive. His strategic vision consistently results in scalable systems, stronger partnerships, and differentiated value propositions in global markets.
Communication:
An articulate communicator who can simplify complex medical and technological concepts for diverse audiences. His collaborative approach encourages open dialogue and enables cross-functional alignment across R&D, commercial, clinical, and executive teams. Whether presenting to global regulators, academic leaders, or internal stakeholders, he communicates with clarity, authenticity, and purpose.
